Molly DiLullo

Molly DiLullo

Auto-generated profile, based on publicly available information

Molly DiLullo

Dana-Farber Cancer Institute 1 Boston

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
BJBojana Jovanović
Bojana Jovanović
SCSarah E. Church
Sarah E. Church
KGKara M. Gorman
Kara M. Gorman
KNKhrystyna North
Khrystyna North
EREdward T. Richardson
Edward T. Richardson
SGShom Goel
Shom Goel
Purpose: Triple-negative breast cancer (TNBC) is a heterogeneous disease that carries the poorest prognosis of all breast cancers. Although novel TNBC therapies in development are frequently targeted toward tumors carrying a specific genomic, transcriptomic, or protein biomarker, it is poorly understood how these biomarkers are correlated. Experimental Design: To better understand the molecular features of TNBC and their correlation with one another, we performed multimodal profiling on a cohort of 95 TNBC. Our approach involved quantifying tumor-infiltrating lymphocytes through hematoxylin and eosin staining, assessing the abundance of retinoblastoma, androgen receptor, and PDL1 proteins through IHC, and carrying out transcriptomic profiling using the NanoString BC360 platform, targeted DNA sequencing on a subset of cases, as well as evaluating associations with overall survival. Results: Levels of RB1 mRNA and RB proteins are better correlated with markers of retinoblastoma functionality than RB1 mutational status. Luminal androgen receptor tumors clustered into two groups with transcriptomes that cluster with either basal or mesenchymal tumors. Tumors classified as PDL1-positive by the presence of immune or tumor cells showed similar biological characteristics. HER2-low TNBC showed no distinct biological phenotype when compared with HER2-zero. The majority of TNBC were classified as basal or HER2-enriched by PAM50, the latter showing significantly improved overall survival. Conclusions: Our study contributes new insights into biomarker utility for identifying suitable TNBC therapies and the intercorrelations between genomic, transcriptomic, protein, and cellular biomarkers. Additionally, our rich data resource can be used by other researchers to explore the interplay between DNA, RNA, and protein biomarkers in TNBC.

5 February 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
SGShom Goel
Shom Goel
BJBojana Jovanović
Bojana Jovanović
XCXiangying Chu
Xiangying Chu
MHMelissa Hughes
Melissa Hughes
TETimothy K. Erick
Timothy K. Erick
STSara M. Tolaney
Sara M. Tolaney
Purpose: Cyclin-dependent kinase 4/6 inhibitors can significantly extend survival when given in combination with endocrine therapy in patients with hormone receptor–positive metastatic breast cancer. However, their activity has been relatively underexplored in patients with metastatic triple-negative breast cancer (mTNBC). Patients and Methods: We conducted a single-arm phase II study of abemaciclib monotherapy in patients with Rb-positive mTNBC. Patients were treated with abemaciclib 200 mg orally twice daily until disease progression, unacceptable toxicity, or withdrawal of consent. The primary endpoint was the objective response rate; secondary endpoints included progression-free survival (PFS), overall survival (OS), clinical benefit rate, disease control rate, and safety and tolerability. Results: A total of 27 patients were enrolled before the trial was closed early because of slow accrual. Patients had received a median of two lines of systemic therapy in the metastatic setting prior to enrollment. After a median follow-up of 28.5 months, the objective response rate was 0%, the clinical benefit rate was 14.8%, and the disease control rate was 22.2%. The median PFS was 1.94 months (95% confidence interval, 1.84–11.47), and the median OS was 8.44 months (95% confidence interval, 4.57–15.57). Median PFS and OS did not differ significantly based on androgen receptor and PD-L1 status. Pretreatment gene expression profiling of tumor tissue provided some hypothesis-generating insights into biological features associated with clinical benefit in this study. The most common treatment-related adverse events of grade 2 or higher were diarrhea (40.7%), neutropenia (40.7%), anemia (29.6%), and nausea (29.6%). Conclusions: Abemaciclib monotherapy did not show clinical activity in patients with pretreated Rb-positive mTNBC.

3 September 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
AGAntonio Giordano
Antonio Giordano
PKPriya U. Kumthekar
Priya U. Kumthekar
QJQingchun Jin
Qingchun Jin
BKBusem Binboga Kurt
Busem Binboga Kurt
SRSiyang Ren
Siyang Ren
NLNancy U.T. Lin
Nancy U.T. Lin
Purpose: Patients with HER2-positive breast cancer brain metastases have few effective systemic therapy options. In a prior study, pertuzumab with high-dose trastuzumab demonstrated a high clinical benefit rate (CBR) in the central nervous system (CNS) in patients with brain metastases. The current trial evaluated whether the addition of atezolizumab to this regimen would produce further improvements in CNS response. Patients and Methods: This was a single-arm, multicenter, phase II trial of atezolizumab, pertuzumab, and high-dose trastuzumab for patients with HER2-positive breast cancer brain metastases. Participants received atezolizumab 1,200 mg i.v. every 3 weeks, pertuzumab (loading dosage 840 mg i.v., then 420 mg i.v. every 3 weeks), and high-dose trastuzumab (6 mg/kg i.v. weekly for 24 weeks, then 6 mg/kg i.v. every 3 weeks). The primary endpoint was CNS overall response rate per Response Assessment in Neuro-Oncology Brain Metastases criteria. Key secondary endpoints included CBR, overall survival, and safety and tolerability of the combination. Results: Among 19 enrolled participants, two had a confirmed intracranial partial response for a CNS overall response rate of 10.5% (90% confidence interval, 1.9%–29.6%). The study did not meet the prespecified efficacy threshold and was terminated early. The CBR was 42.1% at 18 weeks and 31.6% at 24 weeks. Seven patients (36.8%) required a dose delay or hold, and the most frequent any-grade adverse events were diarrhea (26.3%) and fatigue (26.3%). Conclusions: The addition of atezolizumab to pertuzumab plus high-dose trastuzumab does not result in improved CNS responses in patients with HER2-positive breast cancer brain metastases.

20 June 2026 in Annals of Oncology
Verified
Journal Article
Closed access
AGA.C. Garrido-Castro
A.C. Garrido-Castro
SKS.E. Kim
S.E. Kim
TLT. Li
T. Li
JDJ. Desrosiers
J. Desrosiers
RNR. Nanda
R. Nanda
STSara M. Tolaney
Sara M. Tolaney

10 February 2026 in ESMO Open
Verified
Journal Article
Open access
AGAlbert Grinshpun
Albert Grinshpun
DDD. Dustin
D. Dustin
MCM. Cai
M. Cai
MHM. Hughes
M. Hughes
MDM. DiLullo
M. DiLullo
RJR. Jeselsohn
R. Jeselsohn
Neoadjuvant endocrine therapy (NET) is used in hormone receptor (HR)-positive, HER2-negative breast cancer to reduce tumor burden before surgery. However, robust biomarkers to predict benefit from NET are lacking. We evaluated the potential of circulating tumor DNA (ctDNA) before treatment and the dynamics during NET to guide treatment decisions for patients receiving NET. In this retrospective analysis, ctDNA before and after NET from patients enrolled in the phase II PELOPS trial, was assessed using the tissue-free Guardant Reveal assay. ctDNA was detected at the pre-NET timepoint in 37.5% of patients (18/48) and 13.6% (6/44) of patients following NET. Pre-NET ctDNA detection was associated with higher pathological stage and higher residual cancer burden scores after NET. Patients with persistent ctDNA detected pre-surgery had a higher risk of distant recurrence. Taken together, these results support the potential of ctDNA to predict tumor burden before surgery after NET and provide insights into long-term prognosis. ClinicalTrials.gov NCT02764541.

3 December 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
FLFilipa Lynce
Filipa Lynce
NGNoah Graham
Noah Graham
BKBose S. Kochupurakkal
Bose S. Kochupurakkal
HNHuy Nguyen
Huy Nguyen
BBBrittany Bychkovsky
Brittany Bychkovsky
STSara M. Tolaney
Sara M. Tolaney
Purpose: We explored the efficacy of PARP inhibition combined with sapacitabine, an orally bioavailable prodrug of the deoxycytidine analog 2′-C-cyano-2′-deoxy-1-β-D-arabino-pentofuranosylcytosine, in patients with germline BRCA1/2–mutated HER2-negative metastatic breast cancer. Patients and Methods: In this phase Ib investigator-sponsored study of sapacitabine and olaparib, patients who were PARP inhibitor–naïve were enrolled. The primary objective was determination of the recommended phase 2 dose (RP2D) of sapacitabine with olaparib. Archival samples were subjected to IHC for biomarkers of homologous recombination repair (HRR) deficiency and replication stress. Serial blood samples were collected for ctDNA analysis. Results: Ten patients (3 BRCA1 and 7 BRCA2) were enrolled. The RP2D was not determined due to hematologic toxicities. The objective response rate (ORR) was 50% (95% confidence interval, 18.7%–81.3%), with median progression-free survival (mPFS) of 9.7 months (95% confidence interval, 8.02–not estimable). Three patients had clinical benefit greater than 15 months, including two who remained on trial for more than 40 months. Tumors from responding patients demonstrated HRR deficiency and/or replication stress by IHC. At progression, ctDNA from two patients had evidence of BRCA reversion mutations associated with a microhomology-mediated end-joining signature, and three patients had acquired putative nonreversion mechanisms of resistance. Conclusions: Sapacitabine with olaparib produces high rates of hematologic toxicity. However, the ORR of 50%, mPFS of 9.7 months, and durability of response in some patients suggest possible combinatorial benefit. Further exploration of olaparib with different sapacitabine schedules or substitution of a PARP1-selective inhibitor to potentially decrease hematologic toxicity is warranted.